The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP).
Neurochem Res
; 42(7): 1894-1903, 2017 Jul.
Article
in En
| MEDLINE
| ID: mdl-28462454
ABSTRACT
For over 40 years, the National Institute of Neurological Disorders and Stroke/National Institutes of Health-funded Anticonvulsant Screening Program has provided a preclinical screening service for participants world-wide that helped identify/characterize new antiseizure compounds, a number of which advanced to the market for the treatment of epilepsy. The newly-renamed Epilepsy Therapy Screening Program (ETSP) has a refocused mission to identify novel agents which will help address the considerable remaining unmet medical needs in epilepsy. These include identifying antiseizure agents for treatment-resistant epilepsy, as well as anti-epileptogenic agents that will prevent the development of epilepsy or disease-modifying agents that will ameliorate or even cure established epilepsy and its comorbidities. This manuscript provides an overview of the ETSP's efforts aimed at identifying the next generation of therapeutic agents to further reduce the suffering from and burden of epilepsy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Evaluation, Preclinical
/
Epilepsy
/
National Institute of Neurological Disorders and Stroke (U.S.)
/
Anticonvulsants
Type of study:
Diagnostic_studies
/
Screening_studies
Limits:
Animals
/
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Neurochem Res
Year:
2017
Document type:
Article
Affiliation country:
Estados Unidos